Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Ind...

Om AU

A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

DOI

  • Ariane Volkmann, Bavarian Nordic A/S
    • ,
  • Gerrit Koopman, Biomedical Primate Research Centre
    • ,
  • Petra Mooij, Biomedical Primate Research Centre
    • ,
  • Ernst J. Verschoor, Biomedical Primate Research Centre
    • ,
  • Babs E. Verstrepen, Biomedical Primate Research Centre
    • ,
  • Willy M.J.M. Bogers, Biomedical Primate Research Centre
    • ,
  • Manja Idorn
  • Søren R. Paludan
  • Søren Vang
  • Morten A. Nielsen, Københavns Universitet
    • ,
  • Adam F. Sander, Københavns Universitet, AdaptVac Aps
    • ,
  • Carolin Schmittwolf, Bavarian Nordic A/S
    • ,
  • Hubertus Hochrein, Bavarian Nordic A/S
    • ,
  • Paul Chaplin, Bavarian Nordic A/S

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic. Here, we present non-human primate immunogenicity and protective efficacy data generated with the capsid virus-like particle (cVLP)-based vaccine ABNCoV2 that has previously demonstrated immunogenicity in mice. In rhesus macaques, a single vaccination with either 15 or 100 μg ABNCoV2 induced binding and neutralizing antibodies in a dose-dependent manner, at levels comparable to those measured in human convalescents. A second vaccine administration led to a >50-fold increase in neutralizing antibodies, with 2-log higher mean levels in the 100-μg ABNCoV2 group compared with convalescent samples. Upon SARS-CoV-2 challenge, a significant reduction in viral load was observed for both vaccine groups relative to the challenge control group, with no evidence of enhanced disease. Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.

OriginalsprogEngelsk
Artikelnummer857440
TidsskriftFrontiers in Immunology
Vol/bind13
Antal sider10
ISSN1664-3224
DOI
StatusUdgivet - apr. 2022

Se relationer på Aarhus Universitet Citationsformater

ID: 267352656